Johnson & Johnson (NYSE:JNJ) Shares Bought by Modern Wealth Management LLC

Modern Wealth Management LLC increased its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 35.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 33,386 shares of the company's stock after buying an additional 8,769 shares during the quarter. Modern Wealth Management LLC's holdings in Johnson & Johnson were worth $5,149,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. MRP Capital Investments LLC raised its holdings in shares of Johnson & Johnson by 4.1% in the 4th quarter. MRP Capital Investments LLC now owns 1,640 shares of the company's stock worth $237,000 after purchasing an additional 65 shares during the period. Werba Rubin Papier Wealth Management increased its position in Johnson & Johnson by 3.3% during the 4th quarter. Werba Rubin Papier Wealth Management now owns 2,080 shares of the company's stock worth $301,000 after purchasing an additional 66 shares in the last quarter. Denali Advisors LLC lifted its position in Johnson & Johnson by 1.3% during the fourth quarter. Denali Advisors LLC now owns 5,128 shares of the company's stock valued at $742,000 after buying an additional 67 shares in the last quarter. Sage Mountain Advisors LLC grew its stake in Johnson & Johnson by 0.5% during the fourth quarter. Sage Mountain Advisors LLC now owns 14,564 shares of the company's stock worth $2,106,000 after buying an additional 67 shares during the period. Finally, Corepath Wealth Partners LLC increased its position in shares of Johnson & Johnson by 3.7% in the fourth quarter. Corepath Wealth Partners LLC now owns 1,985 shares of the company's stock worth $287,000 after acquiring an additional 70 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Remove Ads

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on JNJ. Bank of America upped their price target on shares of Johnson & Johnson from $159.00 to $171.00 and gave the stock a "neutral" rating in a research report on Wednesday, March 5th. Royal Bank of Canada reiterated an "outperform" rating and issued a $181.00 target price on shares of Johnson & Johnson in a research note on Wednesday, February 19th. Wells Fargo & Company reduced their price target on Johnson & Johnson from $166.00 to $152.00 and set an "equal weight" rating on the stock in a research report on Thursday, January 23rd. Morgan Stanley lowered their price objective on shares of Johnson & Johnson from $175.00 to $163.00 and set an "equal weight" rating for the company in a research report on Thursday, January 23rd. Finally, Raymond James reduced their target price on shares of Johnson & Johnson from $170.00 to $165.00 and set an "outperform" rating on the stock in a research report on Thursday, January 23rd. Nine research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $171.33.

Johnson & Johnson Stock Performance

NYSE:JNJ traded up $0.75 during trading hours on Wednesday, reaching $161.77. 3,680,955 shares of the stock were exchanged, compared to its average volume of 7,070,946. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. The stock has a market capitalization of $389.84 billion, a P/E ratio of 24.32, a P/E/G ratio of 2.56 and a beta of 0.47. The firm has a 50 day simple moving average of $157.70 and a 200-day simple moving average of $156.14.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping analysts' consensus estimates of $1.99 by $0.05. The firm had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The firm's revenue was up 5.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.29 earnings per share. As a group, sell-side analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th were paid a $1.24 dividend. The ex-dividend date of this dividend was Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a yield of 3.07%. Johnson & Johnson's payout ratio is currently 74.59%.

Insider Activity

In other news, EVP Timothy Schmid sold 403 shares of the company's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the transaction, the executive vice president now owns 15,098 shares in the company, valued at approximately $2,357,552.70. This represents a 2.60 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Robert J. Decker sold 6,999 shares of Johnson & Johnson stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the completion of the sale, the vice president now owns 21,001 shares in the company, valued at approximately $3,483,645.88. This represents a 25.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.16% of the company's stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.